This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Safety and outcome of microincision vitreous surgery in uveitis

Safety and outcome of microincision vitreous surgery in uveitis
Reviewed by Nikolaos D Georgakarakos

1 June 2018 | Nikolaos D Georgakarakos | EYE - Vitreo-Retinal

This paper reports the outcomes of microincision vitreous surgery (MIVS) 23G/25G in uveitis of 103 patients (106 eyes) who underwent diagnostic MIVS over a period of four years at the Advanced Eye centre in Chandigarth India. The postoperative evaluation included visual acuity, vitreous haze and complications. The mean follow-up period was 12.2+/-7.2 months (median 12 months) and the mean age was 36.8+/-13.9 years. Mean best corrected visual acuity (BCVA) was 1.5+/-1.0 logMAR preop and 0.72+/-0.68 logMAR at one month (p=0.000). The postoperative complications included – cataract (14.6%), rise in intraocular pressure (13.2%), vitreous haemorrhage (4.7%) hypotony (3.2%), retinal detachment (2.8%), epiretinal membrane (2.8%) and worsening of inflammation (0.9%). There was a significant reduction in vitreous haze postoperatively as early as the next postoperative day. The mechanism by which vitrectomy improves inflammation is not known precisely. Removal of the vitreous that harbours the inflammatory cells / mediators (immune complexes and cytokines) and infectious agents may be responsible for eliminating inflammation. Additionally the authors reported the reduction or cessation in the use of postoperative steroids systemic corticosteroids (or tapered to a low dose <7.5 mg/day) in 67.8% eyes. Overall, the authors found MIVS to be safe and efficacious and well tolerated in the majority of eyes in a wide variety of complicated uveitis cases. 

Safety and outcome of microincision vitreous surgery in uveitis.
Bansal R, Gupta A, Gupta V et al.
OCULAR IMMUMOLOGY AND INFLAMMATION
2017;25(6):775-84.
Share This
CONTRIBUTOR
Nikolaos D Georgakarakos

Moorfields Eye Hospital, London, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency